{"id":553501,"date":"2026-05-03T22:18:43","date_gmt":"2026-05-03T20:18:43","guid":{"rendered":"https:\/\/medizinonline.com\/?p=553501"},"modified":"2026-05-03T22:18:53","modified_gmt":"2026-05-03T20:18:53","slug":"semaglutide-oral-et-decompensation-cardiaque-dans-le-diabete-de-type-2","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/semaglutide-oral-et-decompensation-cardiaque-dans-le-diabete-de-type-2\/","title":{"rendered":"Semaglutide oral et d\u00e9compensation cardiaque dans le diab\u00e8te de type 2"},"content":{"rendered":"\n

L’analyse secondaire de l’essai SOUL publi\u00e9e dans JAMA Internal Medicine<\/em> 2026 d\u00e9montre pour la premi\u00e8re fois que le semaglutide oral r\u00e9duit significativement les \u00e9v\u00e9nements d’insuffisance cardiaque chez les patients pr\u00e9sentant une FHPF pr\u00e9existante – sans signaux de s\u00e9curit\u00e9, m\u00eame en cas de traitement simultan\u00e9 par un inhibiteur du SGLT2. L’insuffisance cardiaque est l’une des complications les plus fr\u00e9quentes et les plus graves du point de vue du pronostic dans le diab\u00e8te de type 2. Les agonistes des r\u00e9cepteurs du GLP-1, en formulation sous-cutan\u00e9e, ont d\u00e9j\u00e0 d\u00e9montr\u00e9 leur efficacit\u00e9 dans la r\u00e9duction des \u00e9v\u00e9nements li\u00e9s \u00e0 l’insuffisance cardiaque. Avec l’analyse secondaire de l’essai SOUL, on dispose d\u00e9sormais pour la premi\u00e8re fois d’un ensemble complet de donn\u00e9es pour la forme orale du semaglutide – et elles montrent : Les r\u00e9sultats en mati\u00e8re d’insuffisance cardiaque sont principalement am\u00e9lior\u00e9s chez les patients dont la fraction d’\u00e9jection est conserv\u00e9e (FEHp), alors qu’aucun effet n’est d\u00e9tect\u00e9 en cas de FE r\u00e9duite (FEHr). Une conclusion qui a une pertinence clinique imm\u00e9diate. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

L’analyse secondaire de l’essai SOUL publi\u00e9e dans JAMA Internal Medicine 2026 d\u00e9montre pour la premi\u00e8re fois que le semaglutide oral r\u00e9duit significativement les \u00e9v\u00e9nements d’insuffisance cardiaque chez les patients pr\u00e9sentant……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":553502,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Insuffisance cardiaque et diab\u00e8te de type 2 ","footnotes":""},"category":[11378,11404,11527,11531,11549],"tags":[18584,14501,17458,91000],"powerkit_post_featured":[],"class_list":["post-553501","post","type-post","status-publish","format-standard","has-post-thumbnail","category-cardiologie","category-endocrinologie-et-diabetologie","category-etudes","category-formation-continue","category-rx-fr","tag-agoniste-du-recepteur-glp-1","tag-hfpef-fr","tag-semaglutid-fr","tag-soul","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-11 02:23:24","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":553482,"slug":"semaglutide-orale-e-scompenso-cardiaco-nel-diabete-di-tipo-2","post_title":"Semaglutide orale e scompenso cardiaco nel diabete di tipo 2","href":"https:\/\/medizinonline.com\/it\/semaglutide-orale-e-scompenso-cardiaco-nel-diabete-di-tipo-2\/"},"pt_PT":{"locale":"pt_PT","id":553479,"slug":"semaglutide-oral-e-descompensacao-cardiaca-na-diabetes-tipo-2","post_title":"Semaglutide oral e descompensa\u00e7\u00e3o card\u00edaca na diabetes tipo 2","href":"https:\/\/medizinonline.com\/pt-pt\/semaglutide-oral-e-descompensacao-cardiaca-na-diabetes-tipo-2\/"},"es_ES":{"locale":"es_ES","id":553498,"slug":"semaglutida-oral-y-descompensacion-cardiaca-en-la-diabetes-tipo-2","post_title":"Semaglutida oral y descompensaci\u00f3n cardiaca en la diabetes tipo 2","href":"https:\/\/medizinonline.com\/es\/semaglutida-oral-y-descompensacion-cardiaca-en-la-diabetes-tipo-2\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/553501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=553501"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/553501\/revisions"}],"predecessor-version":[{"id":553503,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/553501\/revisions\/553503"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/553502"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=553501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=553501"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=553501"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=553501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}